Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has earned an average rating of “Hold” from the seven analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $5.89.

A number of analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of Anthera Pharmaceuticals in a research report on Tuesday, September 19th. ValuEngine upgraded Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research cut Anthera Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 15th. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $1.75 price target (down from $2.25) on shares of Anthera Pharmaceuticals in a research report on Friday, August 11th.

Anthera Pharmaceuticals (ANTH) traded up 3.70% on Friday, reaching $1.40. The company’s stock had a trading volume of 410,618 shares. The company’s market capitalization is $15.27 million. The firm’s 50 day moving average price is $1.35 and its 200-day moving average price is $1.28. Anthera Pharmaceuticals has a 52 week low of $1.20 and a 52 week high of $27.36.

Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.09) by $1.12. On average, equities analysts predict that Anthera Pharmaceuticals will post ($3.68) EPS for the current year.

Several institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. raised its position in shares of Anthera Pharmaceuticals by 1,376.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 335,595 shares during the period. Sabby Management LLC increased its position in Anthera Pharmaceuticals by 1,809.7% in the 1st quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock valued at $748,000 after acquiring an additional 1,665,655 shares during the period. Finally, UBS Group AG increased its position in Anthera Pharmaceuticals by 9.9% in the 1st quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 33,901 shares during the period. Institutional investors and hedge funds own 27.26% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/09/24/anthera-pharmaceuticals-inc-anth-receives-consensus-recommendation-of-hold-from-analysts.html.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Analyst Recommendations for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.